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Abstract
Rationale Hypericum perforatum, popularly called St.
John’s wort (SJW), is a medicinal plant mainly used as
antidepressant with a favorable safety profile than standard
antidepressants. Some studies have also documented other
SJW bioactivities, including pain modulation.
Objectives The aim of this study was to demonstrate the capa-
bility of SJW to relieve nitric oxide (NO)-induced nociceptive
hypersensitivity and identify the effective component.
Methods Nociceptive hypersensitivity induced by adminis-
tration of the NO donors nitroglycerin (GTN) and sodium
nitroprusside (SNP) was assessed by cold and hot plate tests.
The cellular pathways and molecular targets involved were
investigated by Western blotting.
Results GTN and SNP produced a prolonged allodynia and
hyperalgesia in mice. A single oral administration of low
doses of an SJW dried extract or purified hypericin reversed
the NO donor-induced nociceptive behavior whereas hyper-
forin and flavoinoids were ineffective. Investigating into the
cellular pathways involved, an increased CREB and STAT1
phosphorylation, and activation of NF-κBwere detected with-
in PAG and thalamus following NO donors’ administration.
These cellular events were prevented by SJW or hypericin.
Since hypericin showed PKC blocking properties, a role of
PKC as an upstream modulator of these transcription factors
was hypothesized. NO donors increased expression and phos-
phorylation of protein kinase C (PKC) γ and ε isoforms,
molecular events prevented by SJW or hypericin.
Conclusions SJW reversed NO-induced nociceptive hyper-
sensitivity through the blockade of a supraspinal signaling
pathway involving a PKC-dependent CREB, STAT1 and NF-
κB activation due to presence of hypericin. These data indicate
SJW/hypericin as a therapeutic perspective for pain treatment.
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Abbreviations
CREB Cyclic AMP response element binding protein
GTN Nitroglycerin
i.c.v. Intracerebroventricularly
i.p. Intraperitoneally
iNOS Inducible NO synthase
LPS Lipopolysaccharide
NO Nitric oxide
PAG Periaqueductal grey matter
PKC Protein kinase C
SJW St. Jonh’s wort
SNP Sodium nitroprusside
STAT Signal transducer and activator of transcription
Introduction
Nitric oxide (NO) is a free radical that is synthesized by
three isoforms of NOS: neuronal NOS (nNOS), inducible
NOS (iNOS) and endothelial NOS (eNOS) (Bredt et al.
1991; Lamas et al. 1992; Nishida et al. 1992). NO produces
a variety of biological actions under physiological and path-
ological conditions (Harrison 1997; Brown and Bal-Price
2003; Tieu et al. 2003). Among them, the involvement of
NO in acute and chronic pain has been shown. Many animal
studies have shown that NO contributes to the sensitization
during inflammatory and neuropathic pain. The administra-
tion of a NO precursor or a NO donor decreases pain
threshold causing hyperalgesia (Machelska et al. 1998;
N. Galeotti (*) :C. Ghelardini
Department of Preclinical and Clinical Pharmacology,
Viale G. Pieraccini 6,
50139 Florence, Italy
e-mail: nicoletta.galeotti@unifi.it
Psychopharmacology
DOI 10.1007/s00213-012-2950-3
Tassorelli et al. 2003) and potentiates thermal hyperalgesia
and tactile allodynia in neuropathic rats (Naik et al. 2006).
Inhibition of NO synthesis can considerably reduce both
inflammatory and neuropathic pain. NOS inhibitors such
as L-NAME and L-NMMA, which inhibit all three NOS
isoforms in a nonspecific manner, led to a reduction of the
nociceptive behavior in several animal models of inflamma-
tory and neuropathic pain (Luo and Cizkova 2000). More
recent experiments with selective NOS inhibitors and in
NOS-deficient mice confirmed the importance of NO-
producing enzymes in the spinal cord during the develop-
ment and maintenance of inflammatory and neuropathic
pain (Boettger et al. 2007; Guan et al. 2007; Chu et al.
2005; Kuboyama et al. 2011). Furthermore, different studies
have demonstrated the implications of the NO in the anal-
gesic effect of several drugs that are indicated for the treat-
ment of neuropathic pain, such as tramadol (Dal et al. 2006)
and gabapentin (Mixcoatl-Zecuatl et al. 2006), and also in
the antinociceptive effect of anti-inflammatory drugs such as
indomethacin (Ventura-Martinez et al. 2004). It has been
suggested that the analgesic effect of one of the most popular
drugs in the pain treatment, paracetamol (acetaminophen), is
partially mediated through the inhibition of NO generation
(Björkman et al. 1994). Therefore, blocking the strong pain-
sensitizing effects of NO-dependent signaling pathways could
be potentially useful for the management of inflammatory and
neuropathic pain.
Hypericum perforatum L., commonly called St. John’s
wort (SJW), is one of the oldest and best investigated
medicinal herbs. Depressive disorders are the best-known
indication for SJW and preclinical and clinical investiga-
tions have showed its efficacy against mild to moderate
depression with a favorable incidence of side effects than
standard antidepressants (Kasper et al. 2010). In addition to
the antidepressant activity, some studies have documented
other bioactivities produced by SJW as antibacterial
(Saddiqe et al. 2010) and antiviral (Birt et al. 2009) activi-
ties. SJW is also involved in pain processing. It is endowed
with anti-inflammatory activity following topic (Sosa et al.
2007) and systemic administration (Mattace Raso et al.
2002). Recently, the analgesic activity against acute pain
(Galeotti et al. 2010a) and the capability to relieve from
neuropathic pain (Galeotti et al. 2010b) were observed after
oral administration of SJW.
A large body of evidence indicates that NO essentially
contributes to the processing of nociceptive signals in the
spinal cord. NO might signal by various mechanisms in-
cluding cGMP production upon activation of NO-sensitive
guanylyl cyclase (NO-GC), S-nitrosylation, tyrosine nitra-
tion and the interaction with superoxide to form peroxyni-
trite (Bian et al. 2006), even if there is considerable evidence
that NO-GC is the most important NO target during spinal
nociceptive processing. Conversely, the role of NO in
supraspinal pain modulation and the molecular events in-
volved in the NO-mediated signaling pathway are poorly
elucidated. In the present study, we investigated the supra-
spinal cellular and molecular components involved in the
NO-induced pronociceptive activity in an animal model of
NO-induced nociceptive behavior obtained by a peripheral
administration of NO donors. We also investigated the effi-
cacy of an SJW dried extract to relieve the NO-induced
hypernociception. The capability of SJW to counteract the
molecular events modulated by NO donors was studied.
Materials and methods
Animals
Male Swiss albino mice (20–22 g) from the Morini (San Polo
d'Enza, Italy) breeding farm were used. Ten mice were housed
per cage (26×41 cm). The cages were placed in the experimen-
tal room 24 h before the test for acclimatization. The animals
were fed a standard laboratory diet and tap water ad libitum and
kept at 23±1 °C with a 12-h light/dark cycle, lights on at 7 A.M.
The principles of laboratory animal care were followed. All
experiments were carried out in accordance with the
“Guidelines for the Care and Use of Mammals in
Neuroscience and Behavioral Research” (National Research
Council 2003). All efforts were made to minimize animal
suffering, and to reduce the number of animals used.
Drug administration
Animals were randomly assigned to treatment groups. The
NO donors nitroglycerin (GNT) (10 mg/kg; Bioindustria
L.I.M., Italy), dissolved in 10 % ethylene glycol in saline
(0.9 % NaCl), and sodium nitroprusside (SNP) (1 mg/kg;
Sigma, Milan Italy), dissolved in saline, were administered
intraperitoneally (i.p.), and the behavioral tests or sample
collection for Western blotting experiments were performed
1–6 h after i.p. administration.
Hypericum perforatum (SJW) dried extract containing
0.32 % of total hypericins (Indena Research Laboratories,
Settala, Milan Italy) hypericin, hyperforin, hyperoside, quer-
cetin and amentoflavone (Sigma) were dissolved in 1 %
carboxymethylcellulose (CMC) solution immediately be-
fore use and administered by oral gavage. The doses of
hypericin (0.01 mg/kg), hyperforin (0.21 mg/kg), quercetin
(0.0415 mg/kg), amentoflavone (0.0029 mg/kg), hyperoside
(0.3175 mg/kg) correspond to the amount of each compo-
nent present in a 5-mg/kg preparation of SJW dried, the
minimal SJW dose able to counteract NO donors’ nocicep-
tive hypersensitivity.
To investigate the SJW supraspinal mechanism of action,
hypericin (0.1 μg per mouse) and the PKC blocker calphostin
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C (0.2 μg per mouse) (Calbiochem, Milan, Italy), dissolved in
0.5 % DMSO, were administered intracerebroventricularly
(i.c.v.), as previously described (Galeotti et al. 2003).
Behavioral studies
SJWand components were administered 150 min after GNT
or SNP treatment.
Western blotting experiments
Experiments were conducted on periaqueductal grey matter
(PAG) and thalamus of naïve and GTN- and SNP-treated
mice. Brain areas were removed 1, 2, 4 and 6 h after NO
donors’ administration.
For Western blotting experiments, animals were divided in
two groups: (1) SJW (5 mg/kg, p.o.), hypericin (0.01 mg/kg,
p.o.; 0.1 μg per mouse, i.c.v.) or calphostin C administered
10 min before NO donors injection and protein expression
detected 1 or 2 h after GNT/SNP administration; (2) SJW
(5 mg/kg, p.o.), hypericin (0.01 mg/kg, p.o.; 0.1 μg per
mouse, i.c.v.) or calphostin C administered 3 h after NO
donors and protein expression detected 4 or 6 h after GNT/
SNP. Doses and administration schedules were chosen on the
basis of time-course and dose–response curves performed in
our laboratory (Galeotti et al. 2003).
Behavioral testing
Animals were habituated to the experimental room and were
investigated by observers blinded for treatment of the ani-
mals. Ten animals per group were used.
Cold plate
For assessment of cold allodynia, mice were placed on a
cold plate (Ugo Basile, Varese, Italy) maintained at a tem-
perature of 4±0.1 °C. Reaction times (s) were measured
with a stopwatch before and 1, 2, 4 and 6 h after adminis-
tration of the NO donors. The time between placements of a
mouse on the plate and licking or lifting of a hind paw was
measured with a digital timer. An arbitrary cut-off time of
60 s was adopted.
Hot plate
Mice were placed inside a stainless steel container, which
was set thermostatically at 50.0±0.1 °C in a precision water-
bath from KW Mechanical Workshop (Siena, Italy).
Reaction times (s) were measured with a stopwatch before
and 1, 2, 4 and 6 h after administration of the NO donors.
The endpoint used was the licking of the fore or hind paws.
An arbitrary cut-off time of 60 s was adopted.
Western blotting
Preparation of total cell lysates, membrane and cytosol
fractions
Mice were perfused transcardially with 0.9 % NaCl. Brain
areas to conduct Western blotting experiments were collected
1, 2, 4 and 6 h after the GTN (10 mg/kgi.p.) or SNP (1 mg/kg
i.p.) treatment. Mouse brains were dissected to separate spe-
cific areas. Dura mater, PAG and thalamus were homogenized
in an homogenization buffer containing 25 mM Tris–HCl
pH07.5, 25 mM NaCl, 5 mM EGTA, 2.5 mM EDTA,
2 mM NaPP, 4 mM PNFF, 1 mM Na3VO4, 1 mM PMSF,
20 μg/ml leupeptin, 50 μg/ml aprotinin, 0.1 % SDS. The
homogenate was centrifuged at 9,000×g for 15 min at 4 °C,
the low speed pellet was discarded. The supernatant (whole
cell lysate) was centrifugated at 100,000×g for 60min at 4 °C.
The resulting supernatant was the cytosol fraction, and the
pellet was resuspended in the homogenizing buffer containing
0.2 % (wt/vol) Triton X-100. The homogenate was kept at 4 °
C for 60 min with occasional stirring and then centrifugated at
100,000×g for 60 min at 4 °C. The resultant supernatant was
used as membrane fraction. Protein concentration was quan-
tified using Bradford’s method (protein assay kit; Bio-Rad
Laboratories, Milan, Italy).
Western blot analysis
Membrane homogenates (10–50 μg) made from PAG and
thalamus regions of GTN-, SNP-, LPS-treated and naïve
mice were separated on 10 % SDS-PAGE and transferred
onto nitrocellulose membranes (90 min at 120 V) using
standard procedures. Membrane were blocked in PBST
(PBS containing 0.1 % Tween) containing 5 % nonfat dry
milk for 120 min. Following washings, blots were incubated
overnight at 4 °C with specific antibodies against PKCγ
phosphorylated on Thr514 (pPKCγ, 1:1,000 dilution)
(Biosource, Camarillo, CA, USA); PKCγ (1:1,000); PKCε
(1:800); PKCε phosphorylated on Ser729 (pPKCε, 1:750);
IκBα (1:1,000); STAT1 phosphorylated on Tyr701
(pSTAT1, 1:500); β-actin (1:1,000 dilution) (Santa Cruz
Biothechnology Inc., Santa Cruz, CA, USA); CREB
(1:500) or CREB phosphorylated on Ser133 (pCREB,
1:500) (cell Signalling Technology). After being washed
with PBS containing 0.1 % Tween, the nitrocellulose mem-
brane was incubated with goat anti-rabbit horseradish
peroxidase-conjugated secondary antisera (1:10,000) and
left for 1 h at room temperature. Blots were then extensively
washed according to the manufacturer’s instruction and
developed using enhanced chemiluminescence detection
system (Pierce, Milan, Italy). Exposition and developing
time used was standardized for all the blots. Optical density
measurements were performed by dividing the intensity of the
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bands by the intensity of the housekeeping protein β-actin,
used as loading control, at each time point. Measurements in
control samples were assigned a relative value of 100 %.
Statistical analysis
All experimental results are given as the mean ± SEM.
Analysis of variance (ANOVA) followed by Tukey’s post-
hoc test was used for statistical analysis.
Results
SJW prevented nociceptive hypersensitivity induced by NO
donors’ administration
Peripheral administration of GTN (10 mg/kg, i.p.; Fig. 1a) and
SNP (1 mg/kg, i.p.; Fig. 1b) produced a prolonged heat hyper-
algesia as revealed by the hot plate test. The licking latency
values were reduced 2 and 4 h after NO donors’ administra-
tion and returned to control values 6 h after GNT. The effect of
SJWwas, then, evaluated 4 h after NO donors’ treatment. Oral
administration of a 1 mg/kg SJW dried extract was ineffective
whereas at 5 mg/kg completely reversed the heat hyperalgesia
induced by GTN (Fig. 1c) and SNP (Fig. 1d). Investigating
into the main components responsible for the SJW effect, we
observed that the administration of hypericin (hyp; 0.01 mg/
kg, p.o.), when administered in a concentration corresponding
to the content of hypericin present in a 5 mg/kg preparation of
SJW, produced similar results (Fig. 1c,d). Conversely, the
administration of hyperforin (hyf; 0.21 mg/kg) and flavonoids
(flav) hyperoside, amentoflavone and quercetin, was ineffec-
tive (Fig. 1e,f). Flavonoids modified NO donor-induced pain-
ful behaviors neither administered alone (data not shown) nor
in association (Fig. 1e,f).
Following NO donors’ treatment, a cold allodynia was
also observed in the cold plate test that peaked 2 and 4 h
after GTN (Fig. 2a) and SNP (Fig. 2b) administration.
Similar to heat hyperalgesia, cold allodynia induced by
GTN (Fig. 1c) and SNP (Fig. 1d) was completely prevented
by oral administration of SJW and hypericin. Hyperforin
and flavonoids were devoid of any effect (Fig. 2e,f).
Prevention by SJW of activation of the NF-κB pathway
The activation of NF-κB following NO donors’ administra-
tion was examined by immunoblotting in homogenates of
PAG and thalamus after administration of GTN (10 mg/kg,
i.p.) and SNP (1 mg/kg, i.p.). NF-κB is constitutively
inhibited by IκBα. Upon IκBα phosphorylation and degra-
dation, the p65–p50 dimer translocates to the nucleus, pro-
moting gene transcription. After SNP (Fig. 3a) and GTN
(Fig. 3b) administration, we observed a degradation of IκBα
in homogenates of PAG, as indicated by the significant
decrease of protein levels, that peaked after 2 h. At later
time points, the levels of IκBα progressively increased.
SJW administration prevented the activation of the NF-κB
pathway as indicated by the increased levels of IκBα at any
time point. Single oral administration of hypericin (hyp) or
i.c.v. injection of the PKC blocker calphostin C (calph)
significantly reverted the activation of NF-κB pathway pro-
duced by SNP (Fig. 3a) and GTN (data not shown).
A similar pattern of NF-κB activation was observed in
the thalamus following SNP (Fig. 3c) and GTN (Fig. 3d)
administration with a peak of IκBα down-regulation 2 h
after NO donors’ treatment. Oral administration of SJW and
hypericin, or i.c.v. injection of calphostin C prevented the
decrease of the of IκBα content.
SJW prevented the NO donor-induced pSTAT1
up-regulation
A dramatic cerebral increase in the phosphorylated form of
STAT1 was detected following SNP treatment. In the thala-
mus (Fig. 4a) and in the PAG (Fig. 4b), the increase of the
pSTAT1 expression was detected from 1 to 4 h after NO donor
administration with a peak at 2 h. The pSTAT1 contents
returned to control levels 6 h after treatment. The oral
administration of an SJW dried extract completely pre-
vented pSTAT1 up-regulation. A further confirmation of
the modulation of the STAT1 pathway by SJW arises from
experiments conducted in the membrane fraction (Fig. 4c).
A similar time-course and intensity of SNP-induced STAT1
phosphorylation, in comparison with the total lysates, was
obtained in the membrane fraction, effect that was com-
pletely prevented by SJW administration (Fig. 4c). The
absence of any variation in the pSTAT1 contents was
detected in the cytosolic fraction (Fig. 4d). No difference
between the effects produced by GTN and SNP was ob-
served (data not shown).
SJW prevention of CREB activation
A robust increase of the phosphorylated form of CREB
(pCREB) was detected in the whole cell lysate from PAG
after SNP (Fig. 5a) and GTN (Fig. 5b) administration. The
NO donor-induced increase of pCREB was significant 1 h
after administration, peaked between 2 and 4 h and then the
pCREB levels returned comparable to control values. The
oral administration of SJW and hypericin prevented the
increase of pCREB expression at any time point. Similar
results were obtained from experiments conducted on the
total cell lysates from the thalamus following SNP (Fig. 5c)
and GTN (Fig. 5d) administration. The levels of pCREB on
the membrane fraction from PAG showed the same time-
course observed in the whole cell lysate (Fig. 5e). The
Psychopharmacology
modulation by SJW of the phosphorylation of CREB was
demonstrated by the prevention of the increase of pCREB
contents after SJW and hypericin administration (Fig. 5a–e).
SNP produced a drastic decrease of CREB levels in the
whole cell lysates from PAG (Fig. 5f). The reduction of
CREB expression was evident 1 and 2 h after NO donor
administration, then the levels increased and returned to
control values. The reduction of CREB expression was
modulated by SJW since the oral administration of SJW
and its main component hypericin completely reversed the
SNP-induced decrease of CREB protein levels. A reduction
of CREB expression was also observed in the thalamus, and
no difference between the effects produced by GTN and
SNP was observed (data not shown).
SJW counteracts the increased expression
and phosphorylation of PKCγ and PKCε
PAG and thalamus of mice treated with GTN and SNP were
examined for the protein expression and phosphorylation of
the main PKC isoforms involved in pain modulation. The
protein levels were detected in the whole cell lysates, mem-
brane and cytosolic fractions. SNP (Fig. 6a) and GTN
(Fig. 6b) treatment produced a robust and progressive in-
crease of pPKCγ within PAG that peaked 4 h after treat-
ment, returning to control values at 6 h. Oral administration
of SJW dried extract and hypericin (hyp) completely pre-
vented the increase of PKCγ phosphorylation. Within the
thalamus, a PKCγ activation of similar intensity was
detected after SNP (Fig. 6c) and GTN (Fig. 6d) administra-
tion. The time-course of the pPKCγ up-regulation was
comparable to that observed in the PAG. A complete pre-
vention of pPKCγ expression was obtained after SJW and
hypericin administration. To further confirm the supra-
spinal activation of the PKCγ mediated pathway, a dra-
matic increase of the phosphorylation of PKCγ was
observed in the membrane fraction between 1 and 4 h
after NO donor administration, whereas at 6 h the
pPKCγ levels returned to control values. Hypericin pre-
vented the PKCγ hyperphosphorylation at any time point
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40Fig. 1 St. John’s wort (SJW)
prevents the NO donor-induced
nociceptive behavior. Systemic
administration of the NO
donors nitroglycerin (GTN) (a)
or sodium nitroprusside (SNP)
(b) induced heat hyperalgesia in
the hot plate test. A single oral
administration of SJW and
hypericin (hyp), a main compo-
nent of SJW, prevented the
pronociceptive activity of GTN
(c) and SNP (d). Oral adminis-
tration of hyperforin (hyf) and
flavonoids (flav) did not pre-
vent the GTN (e) and SNP (f)
heat hyperalgesia. *P<0.05,
**P<0.01 compared with con-
trol group
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(Fig. 6e). In the cytosolic fraction, the levels of pPKCγ
remained unmodified (Fig. 6f). PKCγ protein expression
was also increased 2 and 4 h after SNP treatment within
PAG (Fig. 6g) and thalamus (Fig. 6h). This increase was
prevented by oral administration of SJW and hypericin.
A robust increase of the phosphorylation of PKCε was
produced by both SNP (Fig. 7a) and GTN (Fig. 7b) within
PAG. Similar to pPKCγ, the pPKCε levels increased be-
tween 2 and 4 h and disappeared 6 h after NO donors’
administration. A similar PKCε activation was observed
within thalamus following SNP (Fig. 7c) and GTN
(Fig. 7d) treatment. SJW and hypericin, orally adminis-
tered, were able to prevent the pPKCε up-regulation at
any time point with a similar efficacy in both cerebral
areas (Fig. 7a–d). Total PKCε protein contents were
also increased 2 and 4 h after NO donor treatment in
the PAG (Fig. 7e) and 2 h after treatment in the thala-
mus (Fig. 7f) with a similar degree of activation.
Treatment of animals with SJW and hypericin prevented
the PKCε up-regulation.
Hypericin prevented NO-induced nociceptive hypersensitivity
through a supraspinal mechanism
The intracerebroventricular administration of hypericin
completely reversed the heat hyperalgesia (Fig. 8a) and cold
allodynia (Fig. 8b) induced by GTN and SNP. Investigating
into the supraspinal cellular events modulated by hypericin,
we observed that the i.c.v. administration of hypericin pre-
vented the decrease of IκBα content and counteracted the
overexpression of pSTAT1, pCREB, pPKCγ and pPKCε
induced by the administration of SNP in the PAG (Fig. 8c)
and in the thalamus. The results obtained were of similar
intensity to those detected following p.o. administration of
SJW and hypericin.
Discussion
We report here the first description of an SJW dried extract
to prevent NO-induced nociceptive hypersensitivity after a
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Fig. 2 St. John’s wort (SJW)
prevents the NO donor-induced
allodynia. GTN (a) and SNP (b)
induced cold allodynia in the
cold plate test. Oral administra-
tion of SJW and hypericin pre-
vented the cold allodynia
induced by GTN (c) and SNP
(d), whereas hyperforin (hyf
and flavonoids (flav) were inef-
fective against GTN (e) and
SNP (f) allodynic effect. *P<
0.05, **P<0.01, ***P<0.001
compared with the control
group
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single oral administration. The systemic administration of
the NO donors GTN and SNP produced a prolonged thermal
allodynia and hyperalgesia in mice, further confirming the
essential contribution of NO for nociceptive processing. A
single oral administration of a low dose of an SJW dried
extract reversed the pronociceptive effect induced by NO
donors. The dose of SJW used (0.016 mg of total hyper-
icins) was considerably lower than those required to induce
antidepressant (1.8–2.7 mgday−1 of total hypericins)
(Kasper et al. 2010) and analgesic activities (0.96 mg of
total hypericins) (Galeotti et al. 2010a,b). We can suppose
that SJW relief from NO-induced nociceptive hypersensitiv-
ity in this animal model is not secondary to its antidepres-
sant or analgesic property.
To clarify the supraspinal cellular pathways involved in
the NO-induced nociceptive behavior, we detected the ex-
pression of transcription factors involved in the modulation
of inflammation and pain processing, such as nuclear factor-
κB (NF-κB), Signal Transducer and Activator of
Transcription (STAT)-1, cyclic AMP response element bind-
ing protein (CREB), within PAG and thalamus. The activa-
tion of the NF-κB pathway after GTN and SNP was
demonstrated by the consistent down-regulation of IκBα
protein expression. NF-κB consists of dimers that under
basal condition are sequestered within the cytoplasm by
the IκB family of inhibitory proteins. Phosphorylation of
IκBα triggers its ubiquination and rapid degradation, there-
by releasing NF-κB to initiate expression of iNOS, cyto-
kines (IL-1β, IL6) and molecules involved in inflammation
and pain perception (Oeckinghaus et al. 2011). The decrease
of IκBα protein expression was prevented by oral adminis-
tration of an SJW dried extract showing the capability of this
herbal medicine to counteract supraspinal cellular events
involved in inflammation and nociceptive hypersensitivity
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Fig. 3 Effect of SJWon IκBα expression. a SNP activated supraspinal
NF-κB pathway within PAG as indicated by the reduced levels of
IκBα. The activation of the NF-κB pathway was prevented by SJW,
hypericin (hyp) and the PKC blocker calphostin C (calph). b Within
PAG SJW also prevented the IκBα down-regulation produced by GTN
administration. A cerebral activation of the NF-κB pathway is
indicated by the reduction of IκBα levels in the thalamus following
SNP (c) and GTN (d). A single oral administration of SJW, hypericin
and calphostin C prevented the NO donor-induced activation of the
NF-κB pathway. *P<0.05, **P<0.01, ***P<0.001 compared with the
control group (C). °P<0.05, °°P<0.01, °°°P<0.001 compared with
corresponding NO donor-treated group
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produced by NO. These results are in agreement with pre-
vious reports attributing the anti-inflammatory property of
SJW to the inhibition of the NF-κB activation (Bork et al.
1999).
STAT proteins possess the ability to transduce signals
from the cell membrane to the nucleus to activate gene
transcription, thus bypassing the involvement of secondary
messengers. STAT proteins are activated by a plethora of
cytokines, including interferons and interleukins, as well as
growth factors and hormones (Lim and Cao 2006) and the
relevance of the STAT pathways in the response to cyto-
kines and inflammation is widely known. In the mouse
model of NO-induced nociceptive behavior we observed a
dramatic increase in the expression of the phosphorylated
form of STAT1 (pSTAT1) following NO donors’ injection
within PAG and thalamus with a time-course consistent with
the nociceptive behavior. We, then, might suggest that the
NO donor-induced supraspinal pSTAT1 up-regulation might
participate to the pronociceptive activity. The administration
of SJW completely prevented the pSTAT1 up-regulation at
any time point detected. The capability of SJW to inhibit
iNOS expression by down-regulating STAT1α activation
was observed in human epithelial cell lines at concentrations
consistent with those used in the present study (Tedeschi et
al. 2003), confirming the involvement of this transcription
factor in the mechanism of anti-inflammatory action of the
investigated herbal drug.
CREB plays an important role in the inflammatory process-
es and in the modulation of pain perception. In the early stages
of inflammation (Ji and Rupp 1997) and sciatic nerve injury
(Ma and Quirion 2001), the phosphorylation of CREB is
increased. Furthermore, this transcription factor regulates
long-lasting effects of NO in neurons (Contestabile 2008).
Following GTN and SNP treatment, we detected a robust
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increase in the phosphorylation of CREB within PAG and
thalamus, in coincidence with the presence of allodynia and
hyperalgesia. Oral administration of SJW drastically reduced
pCREB levels. These results illustrate a relevant influence of
SJWon CREB expression and phosphorylation and support the
possibility that CREB signaling pathway may play an impor-
tant role in the modulation of pain processing produced by NO.
SJW contains a number of bioactive compounds (Barnes et
al. 2001). Among them, hypericin appears of particular rele-
vance since behavioral experiments showed that hypericin was
able to reverse cold allodynia and thermal hyperalgesia induced
by NO donors with the same pharmacological profile of SJW
whereas hyperforin and flavonoids were ineffective. To clarify
the cellular mechanism of SJW, we focused our attention on the
molecular pathways modulated by hypericin. Enzyme assays
performed on rat brain demonstrated that hypericin is a potent
and selective inhibitor of the protein kinase C (PKC)
(Takahashi et al. 1989), enzyme highly involved in pain mod-
ulation (Velazquez et al. 2007). PKC is a family of serine/
threonine kinases that are divided into three groups based on
calcium and diacylglicerol dependence: conventional (α, βI,
βII, γ), novel (δ, ε, η, θ), atypical (ζ, λ/ι) (Way et al. 2000).We
examined the involvement of PKCε and PKCγ since they
appear to be the isoforms with a prominent role in the modu-
lation of pain perception (Velazquez et al. 2007). We detected a
specific up-regulation and increased phosphorylation of PKCε
and PKCγ isoforms in PAG and thalamus of GTN and SNP
treated mice. The oral administration of SJW and hypericin
prevented the NO donor-induced hyperphosphorylation of both
PKC isoforms. The blockade of PKC activity appears a funda-
mental step in the mechanism of action through which SJW
modulates pain processing since also its analgesic and antineur-
opathic activity is related to the prevention of cerebral PKC
hyperphosphorylation (Galeotti et al. 2010a,b). The transloca-
tion of these enzymes from cytosol to the synaptic membrane is
thought to be necessary for their activation (Nishizuka 1992).
We observed a robust increase of the PKCε and PKCγ isoform
phosphorylation in the membrane fraction, whereas a lack of
increase in any of the phosphorylation of PKCε and PKCγ in
the cytosol was detected, confirming the specific PKC activa-
tion in this murine model. Treatment with SJW, hypericin or the
PKC blocker calphostin C prevented the increased phosphory-
lation of PKCε and PKCγ in the membrane fraction, further
demonstrating that the inhibition of PKC hyperphosphorylation
induced by SJW is consequent to the PKC blocking property of
hypericin. Furthermore, similarly to SJW, purified hypericin
was also able to counteract the activation of the NF-κB, STAT1
and CREB signaling pathways, further confirming hypericin as
a major SJW component involved in the reduction of NO-
induced nociceptive behavior. Following the i.c.v. administra-
tion of hypericin, the reversal of the nociceptive behavior
induced by NO donors’ administration was obtained. The same
treatment also prevented the NO-induced IκBα decrease and
the pSTAT1, pCREB, pPKCγ and pPKCε overexpression in
the PAG and thalamus with intensity comparable to that ob-
served after oral administration. These results further confirm a
supraspinal mechanism of action of hypercin.
These results have highlighted the presence of a PKC-
mediated pathway in the supraspinal nociceptive processing
following NO donor administration that might represent a
molecular target of SJW. In particular, we can suppose that
PKC might act as an upstream regulator of NF-κB, STAT1
and CREB. The hypothesis of the activation of the PKC/NF-
κB pathway following NO donors’ administration, that con-
tributes to the induction of allodynia/hyperalgesia, was con-
firmed by studies conducted on murine microglia showing
that LPS- and peptidoglycan-induced iNOS production
appears to be mediated by a signaling pathway involving
the sequential of PKC and NF-κB activation (Bhatt et al.
2010; Wen et al. 2011). Similarly, we can suppose that PKC
might be involved in the NO-induced supraspinal activation
of STAT1. This hypothesis is supported by the observation
that blockade of conventional PKC isoenzymes down-
regulate STAT1 activation in LPS-treated murine macro-
phages (Salonen et al. 2006). We, then, might hypothesize
that CREB, STAT1 and NF-κB, acting as downstream effec-
tors of PKC, can cooperatively modulate the sensation of
pain to produce a condition of hypersensitivity to noxious
stimuli. It appears plausible to suppose that SJW prevents
the nociceptive behavior in response to NO donor adminis-
tration by inhibiting a PKC-dependent intracellular pathway
involving CREB, STAT1 and NF-κB through the activity of
hypericin (see Fig. 9).
A number of antidepressants are routinely used in the
treatment of chronic pain conditions and the involvement of
the monoaminergic pathways in the modulation of pain per-
ception has long been known. Receptor binding and enzyme
inhibition assays carried out using hypericum extract demon-
strated significant affinity for MAOA, MAOB and inhibitory
activity towards synaptosomal uptake of serotonin, dopamine
and noradrenaline. The MAO-inhibitory properties of SJW
Fig. 6 SJW prevented the up-regulation and increased phosphoryla-
tion of PKCγ induced by NO donors’ administration. Systemic admin-
istration of GNT (a) and SNP (b) increased the expression of pPKCγ
within PAG 2 and 4 h after administration that was completely pre-
vented by oral administration of SJW and hypericin. SNP (c) and GTN
(d) up-regulated pPKCγ within the thalamus. SJW and hypericin
counteracted the PKCγ hyperphosphorylation. e SNP produced a
cerebral activation of the PKCγ pathways as confirmed by the in-
creased expression of pPKCγ within the PAG membrane fraction that
was prevented by hypericin. f Lack of effect on pPKCγ protein levels
in the cytosolic fraction following NO donor and hypericin adminis-
tration. SJW and hypericin prevented the PKCγ up-regulation induced
by SNP treatment within the PAG (g) and thalamus (h). *P<0.05,
**P<0.01, ***P<0.001 compared with the control group (C).
°P<0.05, °°P<0.01, °°°P<0.001 compared with the corresponding
NO donor-treated group
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were mainly due to hypericin, but the MAO inhibition was
obtained in vitro with concentrations of extracts too high
(>100 μg/ml) to be achieved in vivo (Bladt and Wagner
1994; Yu 2000). The inhibition of monoamine synaptosomal
uptake of SJW is related to the presence of hyperforin. The
amount of hyperforin present in the SJW concentration used
in the present study was ineffective on modulating the pain
threshold and, therefore, we can exclude the inhibition of the
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Fig. 7 Oral administration of SJWand hypericin prevented NO donor-
induced supraspinal PKCε activation. SNP (a) and GTN (b) activated
the PKCε pathway as indicate by the increased expression of pPKCε
within PAG that was prevented by administration of SJW and hyper-
icin. Within the thalamus, SNP (d) and GTN (e) systemic treatment up-
regulated pPKCε. Oral administration of SJW and hypericin prevented
the No donor-induced increase of pPKCε expression. The same treat-
ment also prevented the total PKCε protein increase within PAG (e)
and thalamus (f). *P<0.05, **P<0.01, ***P<0.001 compared with
control group (C); °P<0.05, °°P<0.01, °°°P<0.001 compared with
corresponding NO donor-treated group
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monoamine reuptake as a mechanism of the SJW antihyper-
algesic activity in this model. The involvement of the adren-
ergic system can be further ruled out since the α2-
adrenoceptor antagonist yohimbine did not prevent SWJ,
hyperforin and hypericin induced antinociception, as recently
demonstrated (Galeotti et al. 2010a).
With regard to the development of novel analgesics that
might act through NO, it is important to consider that this
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Fig. 8 Intracerebroventricular
(i.c.v.) administration of
hyperforin prevents the NO
donor-induced nociceptive be-
havior and cellular modulation. a
Nitroglycerin (GTN) or sodium
nitroprusside (SNP) induced heat
hyperalgesia in the hot plate test
prevented by a single i.c.v. in-
jection of hypericin (hyp). b
Intracerebroventricular hypericin
also prevented NO-induced cold
allodynia. c Following i.c.v. ad-
ministration, hypericin (hyp)
counteracted the SNP-induced
activation of the NF-κB path-
ways, as demonstrated by the
reduction of the IκBα levels, and
hyperphosphorylation of STAT1,
CREB, PKCγ and PKCε within
PAG. **P<0.01, ***P<0.001
compared with the control group
(CTRL); °°P<0.01, °°°P<0.001
compared to the corresponding
NO donor-treated group
Fig. 9 A proposed model for NO-induced nociceptive behavior in the
mouse brain. Under resting conditions, the transcription factors NF-
κB, CREB and STAT1 reside inactive in the cytoplasm. NF-κB resides
inactivated by inhibitory proteins κB (IκB). CREB and STAT1 are non-
phosphorylated. NO increases phosphorylation of PKCγ isoform that
phosphorylates CREB, STAT1 and IκB proteins. Once phosphorylated,
IκB family members dissociate from NF-κB. NF-κB, pCREB and
pSTAT1 act in the nucleus, binding specific recognition elements in
the promoter regions of genes, thereby activating their transcription
and leading to nociceptive hypersensitivity. SJW, through inhibition of
the PKC phosphorylation, inhibits the NF-κB-CREB- and STAT1-
dependent transcriptional activation to prevent nociceptive behavior
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molecule is involved in many physiological and pathophys-
iological processes throughout the body. Thus, if unspecific
inhibitors of NO are administered systemically, a variety of
potential side effects, especially in the vascular system, have
to be considered. Conversely, SJW is endowed with a fa-
vorable tolerability and safety profile (Rahimi et al. 2009)
and might represent a valid alternative to NO inhibitors to
produce pain relief. Recently, interactions of SJW with
prescription drugs have been reported. SJW, at the dose
recommended for the treatment of mild to moderate depres-
sion, is a potent inducer of cytochrome P450 enzymes
resulting in decrease plasma concentration of a number of
drugs used in co-medication (Whitten et al. 2006). Recent
studies show that the degree of enzyme induction by SJW
correlates strongly with the amount of hyperforin found in
the product. High-dose hyperforin extracts (>10 mgday−1)
had outcomes consistent with CYP3A induction whereas
low-dose hyperforin extracts (<4 mgday−1) demonstrated
no significant effect on CYP3A (Whitten et al. 2006;
Madabushi et al. 2006). We observed that SJW reduced
NO induced nociceptive behavior at very low doses con-
taining an amount of hyperforin (0.21 mg) unable to pro-
duce clinical significant interactions.
In conclusion, present results demonstrated the activation
of a supraspinal signaling pathway involving a PKC-
dependent NF-κB, STAT1 and CREB activation following
systemic NO donors’ administration. A single oral adminis-
tration of SJW or hypericin reverted the nociceptive behavior
and the hyperphosphorylation of the transcription factors. Due
to the efficacy and favorable safety profile, we can suppose
that this herbal plant represents an important therapeutic per-
spective for the treatment of nociceptive hypersensitivity.
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